The Use of Monoclonal Antibody-Based Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors in the Treatment of Hypercholesterolemia.

MLA

Parikh, Riya R., et al. “The Use of Monoclonal Antibody-Based Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors in the Treatment of Hypercholesterolemia.” Cureus, vol. 14, no. 6, June 2022, p. e25641. EBSCOhost, https://doi.org/10.7759/cureus.25641.

APA

Parikh, R. R., Breve, F., Magnusson, P., Behzadi, P., & Pergolizzi, J. (2022). The Use of Monoclonal Antibody-Based Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors in the Treatment of Hypercholesterolemia. Cureus, 14(6), e25641. https://doi.org/10.7759/cureus.25641

Chicago

Parikh, Riya R, Frank Breve, Peter Magnusson, Payam Behzadi, and Joseph Pergolizzi. 2022. “The Use of Monoclonal Antibody-Based Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors in the Treatment of Hypercholesterolemia.” Cureus 14 (6): e25641. doi:10.7759/cureus.25641.